What is the appropriate treatment for a child who ingested a 150 mg tablet of amodiaquine?

Treatment of Amodiaquine Ingestion in Children

Immediate supportive care and symptomatic management are the primary treatment approaches for a child who has ingested amodiaquine 150mg, as there is no specific antidote available.

Initial Management

The treatment focuses on supportive and symptomatic care rather than specific antidotal therapy. Based on general principles of pediatric toxic ingestion management 1, the approach should include:

Immediate Assessment and Stabilization

• Airway, breathing, and circulation must be secured immediately
• Monitor vital signs closely, particularly:
  • Heart rate (amodiaquine causes concentration-dependent bradycardia) 2
  • Blood pressure (expect hypotension at toxic doses) 2
  • Cardiac rhythm and QT interval (risk of QT prolongation) 2

Expected Toxic Effects

Based on the known pharmacology of amodiaquine, anticipate:

• Cardiovascular effects: Bradycardia (mean decrease of 1.9 beats/min per 100 nmol/L drug concentration), hypotension (systolic BP decrease of 1.5-1.7 mmHg per 100 nmol/L), and QT interval prolongation (1.4 ms per 100 nmol/L) 2
• Neurological effects: Acute dystonic reactions have been reported, even with therapeutic dosing 3
• Metabolic complications: The drug undergoes hepatic metabolism via CYP3A4 to potentially toxic quinoneimine metabolites that can cause ferroptosis-mediated liver injury 4

Specific Treatment Measures

Decontamination

• Activated charcoal may be considered if the child presents within 1-2 hours of ingestion and can protect the airway 1
• Gastric lavage is generally not recommended unless massive ingestion occurred within the preceding hour

Symptomatic Management

For bradycardia:

• Monitor continuously with cardiac telemetry
• If symptomatic or severe (heart rate <60 in older children, <80 in infants), consider atropine:
  • Pediatric dose: 0.02 mg/kg IV/IO 5
  • May repeat as needed

For hypotension:

• Intravenous fluid resuscitation with isotonic crystalloids
• If refractory, consider vasopressor support

For QT prolongation:

• Continuous cardiac monitoring
• Correct electrolyte abnormalities (potassium, magnesium, calcium)
• Avoid other QT-prolonging medications

For dystonic reactions (if they occur):

• Diphenhydramine 1-2 mg/kg IV/IM (maximum 50 mg)
• Or benztropine in older children

Monitoring and Laboratory Assessment

• Serial vital signs every 15-30 minutes initially
• Continuous cardiac monitoring for at least 6-8 hours or until drug effects resolve
• Electrocardiograms at baseline and serially to monitor QT interval
• Liver function tests (AST, ALT) as amodiaquine can cause hepatotoxicity 4
• Complete blood count to monitor for potential hematologic effects
• Electrolytes (particularly potassium and magnesium for cardiac stability)

Duration of Observation

Given that amodiaquine is metabolized to the active metabolite desethylamodiaquine with prolonged effects 2, observe for at least 12-24 hours or until all symptoms resolve and vital signs normalize.

Important Caveats

• No specific antidote exists for amodiaquine toxicity
• The severity of toxicity is concentration-dependent 2, but plasma levels are not readily available for clinical decision-making
• Dystonic reactions may be idiosyncratic 3 and can occur even at therapeutic doses, so maintain high vigilance
• Ferroptosis inhibitors (like deferoxamine) have shown protective effects in animal models 4, but their role in human amodiaquine poisoning is not established
• Contact your regional poison control center for additional guidance and to report the case

The 150mg dose represents a significant overdose for most children (therapeutic dosing is approximately 10 mg/kg), making close monitoring and aggressive supportive care essential.